Hubbry Logo
N-MycN-MycMain
Open search
N-Myc
Community hub
N-Myc
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
N-Myc
N-Myc
N-Myc
View on Wikipedia
from Wikipedia

MYCN
Identifiers
AliasesMYCN, MODED, N-myc, NMYC, ODED, bHLHe37, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, MYCN proto-oncogene, bHLH transcription factor, MYCNsORF, MYCNsPEP
External IDsOMIM: 164840; MGI: 97357; HomoloGene: 3922; GeneCards: MYCN; OMA:MYCN - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4613

18109

Ensembl

ENSG00000134323

ENSMUSG00000037169

UniProt

P04198

P03966

RefSeq (mRNA)

NM_005378
NM_001293228
NM_001293231
NM_001293233

NM_008709

RefSeq (protein)

NP_001280157
NP_001280160
NP_001280162
NP_005369

NP_032735

Location (UCSC)Chr 2: 15.94 – 15.95 MbChr 12: 12.99 – 12.99 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

N-myc proto-oncogene protein also known as N-Myc or basic helix-loop-helix protein 37 (bHLHe37), is a protein that in humans is encoded by the MYCN gene.

Function

[edit]

The MYCN gene is a member of the MYC family of transcription factors and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the cell nucleus and must dimerize with another bHLH protein in order to bind DNA.[5] N-Myc is highly expressed in the fetal brain and is critical for normal brain development.[6]

The MYCN gene has an antisense RNA, N-cym or MYCNOS, transcribed from the opposite strand which can be translated to form a protein product.[7] N-Myc and MYCNOS are co-regulated both in normal development and in tumor cells, so it is possible that the two transcripts are functionally related.[8] It has been shown that the antisense RNA encodes for a protein, named NCYM, that has originated de novo and is specific to human and chimpanzee. This NCYM protein inhibits GSK3b and thus prevents MYCN degradation. Transgenic mice that harbor human MYCN/NCYM pair often show neuroblastomas with distant metastasis, which are atypical for normal mice. Thus NCYM represents a rare example of a de novo gene that has acquired molecular function and plays a major role in oncogenesis.[9]

Clinical significance

[edit]

Amplification and overexpression of N-Myc can lead to tumorigenesis. Excess N-Myc is associated with a variety of tumors, most notably neuroblastomas where patients with amplification of the N-Myc gene tend to have poor outcomes.[10][11][12] MYCN can also be activated in neuroblastoma and other cancers through somatic mutation.[13] Intriguingly, recent genome-wide H3K27ac profiling in patient-derived NB samples revealed four distinct SE-driven epigenetic subtypes, characterized by their own and specific master regulatory networks. Three of them are named after the known clinical groups: MYCN-amplified, MYCN non-amplified high-risk, and MYCN non-amplified low-risk NBs, while the fourth displays cellular features which resemble multipotent Schwann cell precursors. Interestingly, the cyclin gene CCND1 was regulated through distinct and shared SEs in the different subtypes, and, more importantly, some tumors showed signals belonging to multiple epigenetic signatures, suggesting that the epigenetic landscape is likely to contribute to intratumoral heterogeneity.[14]

Interactions

[edit]

N-Myc has been shown to interact with MAX.[15][16]

N-Myc is also stabilized by aurora A which protects it from degradation.[17] Drugs that target this interaction are under development, and are designed to change the conformation of aurora A. Conformational change in Aurora A leads to release of N-Myc, which is then degraded in a ubiquitin-dependent manner.[18]

Being independent from MYCN/MAX interaction, MYCN is also a transcriptional co-regulator of p53 in MYCN-amplified neuroblastoma.[citation needed] MYCN alters transcription of p53 target genes which regulate apoptosis responses and DNA damage repair in cell cycle. This MYCN-p53 interaction is through exclusive binding of MYCN to C-terminal domains of tetrameric p53. As a post-translational modification, MYCN binding to C-terminal domains of tetrameric p53 impacts p53 promoter selectivity and interferes other cofactors binding to this region.[19]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

N-Myc

View on Grokipedia
from Grokipedia
N-Myc, encoded by the MYCN proto-oncogene on chromosome 2p24, is a nuclear belonging to the family of basic helix-loop-helix (bHLH-LZ) proteins, which also includes c-Myc and L-Myc. This protein, consisting of 464 with a molecular weight of approximately 49 kDa, functions primarily by forming heterodimers with the Max protein to bind canonical DNA sequences (5'-CACGTG-3'), thereby activating or repressing target genes involved in cellular processes such as proliferation, growth, , and differentiation. Discovered in 1983 through the identification of amplified DNA sequences in cells homologous to c-Myc, N-Myc plays a pivotal role in embryonic development, particularly in neural crest-derived tissues and the , where its expression peaks during early stages and declines with differentiation. In normal cellular physiology, N-Myc regulates key pathways by upregulating genes associated with , protein synthesis, and progression, including cyclins, CDKs, and factors that promote G1/S and G2/M transitions. It interacts with co-factors like WDR5 and Aurora-A to stabilize its activity and influences suppression via targets such as and inhibition, ensuring balanced proliferation during . Dysregulation of N-Myc, often through , leads to its overexpression and oncogenic transformation; this is most prominently observed in 20-25% of neuroblastomas, where MYCN amplification correlates with advanced-stage disease, rapid tumor growth, , and poor patient . Beyond neuroblastoma, N-Myc amplification or overexpression contributes to other malignancies, including , , and certain lung and liver cancers, driving aggressive phenotypes through enhanced cell survival, metabolic reprogramming, and resistance to therapy. Its stability is tightly controlled by and ubiquitination pathways, such as those involving FBW7 and Aurora-A, which, when disrupted, exacerbate its proto-oncogenic potential. Ongoing targets N-Myc for therapeutic intervention, highlighting its central role in cancer biology as a and actionable driver.

Genetics and Discovery

Gene Structure and Location

The MYCN gene, which encodes the N-Myc protein, is located on the short arm of human chromosome 2 at the cytogenetic band 2p24.3, spanning approximately 6.5 kb of genomic DNA. The gene consists of three exons separated by two introns, with the full-length transcript (ENST00000281043.4) measuring about 2.6 kb in mature mRNA form. Exon 1 is non-coding and forms part of an extended 5' untranslated region (UTR), while exons 2 and 3 contain the coding sequence. The primary protein isoform encoded by MYCN comprises 464 amino acids, with a calculated molecular weight of approximately 49.6 kDa. Alternative splicing patterns involve two possible first exons (1a and 1b), which splice to a shared acceptor site in exon 2 before joining exon 3; these generate transcript variants differing in the 5' UTR, which influence translational efficiency but encode the same 464-amino-acid protein isoform. The promoter region is GC-rich and bidirectional, regulating transcription of MYCN in the sense orientation and the adjacent NCYM gene in the antisense direction; it features two potential TATA boxes in the 5' UTR, with the upstream one likely serving as the primary transcription start site. MYCN exhibits strong evolutionary conservation across vertebrates, reflecting its fundamental role in developmental processes, with a direct ortholog in mice denoted as Mycn on 12. Sequence similarity in the basic helix-loop-helix (bHLH) domain and other functional motifs is high between human and murine versions, underscoring shared regulatory mechanisms.

Historical Discovery

The N-Myc proto-oncogene, now designated MYCN, was first identified in 1983 through independent studies by two research groups investigating DNA amplification in human . Schwab et al. reported the discovery of a DNA sequence amplified up to 140-fold in multiple neuroblastoma cell lines, which shared limited homology with the cellular oncogene c-myc but was distinct from it; this sequence was designated N-myc. Concurrently, Kohl et al. cloned the gene from amplified regions in neuroblastoma cell lines and a , confirming its transposition and amplification as a novel -related sequence with partial similarity to v-myc from avian myelocytomatosis virus. These findings established N-Myc as a member of the Myc family, initially defined by its homology to c-myc. Initial cloning efforts further characterized N-Myc's structure and evolutionary relationships. In 1985, a partial cDNA was isolated from a neuroblastoma cell line, revealing conserved regions with c-myc. The full-length cDNA was cloned in 1986, encoding a 464-amino-acid protein with significant homology to c-myc, including basic helix-loop-helix (bHLH) motifs suggestive of DNA-binding capability. Shortly thereafter, L-Myc was identified in 1985 as another Myc family member amplified in small cell lung cancer, sharing homology with both c-myc and N-Myc in specific domains, thereby expanding the family to three related genes. Early 1980s studies, including a 1984 analysis of untreated neuroblastomas, linked N-Myc amplification to aggressive tumor phenotypes, with amplified cases correlating strongly with advanced disease stages and poor prognosis in 38% of patients examined. Cytogenetic mapping placed the N-Myc gene on soon after its discovery. Using human-rodent hybrid cells, Kanda et al. assigned it to in 1983, with refinements to the 2p23-p24 band reported by Schwab et al. in 1984 and further specified to 2p24 by 1987. The protein's role as a was confirmed in the late through its bHLH structure and nuclear localization, akin to c-myc. In the , functional studies solidified this, demonstrating N-Myc's ability to heterodimerize with Max and bind sequences to regulate , with seminal work identifying downstream targets involved in proliferation and development.

Molecular Structure and Expression

Protein Domains and Modifications

The N-Myc protein comprises 464 and is characterized by three primary functional domains: an N-terminal (TAD), a central region, and a C-terminal basic helix-loop-helix (bHLH-LZ) domain. The TAD, spanning residues 1–143, is intrinsically disordered and contains conserved Myc boxes critical for transcriptional , including Myc box I (MBI; residues 45–63) and Myc box II (MBII; residues 110–126). MBI harbors key regulatory motifs such as the phosphodegron sequence, while MBII facilitates interactions with coactivators like acetyltransferases. The central region includes a nuclear localization signal (NLS) that mediates import into the nucleus, ensuring N-Myc's role as a nuclear . The bHLH-LZ domain at the C-terminus (~residues 365–464) enables sequence-specific DNA binding to E-box motifs (CACGTG) and heterodimerization with Max, which is essential for transcriptional function. Due to high sequence homology in this domain across Myc family members, structural insights from c-Myc:Max complexes apply to N-Myc; X-ray crystallography reveals a parallel four-helix bundle upon dimerization, with the basic region inserting into the DNA major groove (PDB: 1NKP). Additionally, nuclear magnetic resonance (NMR) studies of the isolated N-Myc bHLH-LZ show it as largely unstructured in isolation but adopting a stable helical conformation upon Max binding. NMR analysis of the N-Myc TAD further demonstrates transient helical propensities in regions like residues 77–86 and 122–132, contributing to its dynamic interaction landscape. N-Myc activity and stability are tightly controlled by post-translational modifications. at Ser62 within MBI, mediated by kinases such as CDK1 and ERK, enhances and stabilizes the protein, whereas subsequent at Thr58 by GSK3β creates a for the E3 ubiquitin ligase FBXW7, promoting ubiquitination and proteasomal degradation. Ubiquitination primarily targets N-Myc for turnover via the ubiquitin-proteasome system, with FBXW7 acting as the key regulator during . by the histone acetyltransferases p300 and CBP, particularly in the TAD, inhibits ubiquitination and thereby increases N-Myc protein stability.

Expression Patterns and Regulation

N-Myc exhibits high expression during embryonic development, particularly in derivatives such as the central and peripheral nervous systems, as well as in the heart and lung, where it supports proliferation and organ . In contrast, N-Myc levels are markedly low or undetectable in most adult tissues, reflecting its restricted role post-development. This spatiotemporal pattern underscores N-Myc's importance in early growth and differentiation processes, with dysregulation often linked to developmental defects in models. Transcriptional regulation of N-Myc is governed by upstream super-enhancers enriched in H3K27 marks, which recruit factors like and core regulatory circuitry transcription factors (e.g., HAND2, ISL1, PHOX2B) to drive high-level expression in cells. These enhancers, often spanning large genomic regions, facilitate N-Myc activation in response to developmental cues and contribute to its overexpression when amplified. At the post-transcriptional level, N-Myc mRNA stability is modulated by AU-rich elements in the 3' (3' UTR), which interact with stabilizing proteins like to prevent rapid degradation. Additionally, microRNAs such as miR-34a directly target the N-Myc 3' UTR, suppressing translation and promoting differentiation in contexts. Epigenetic control involves acetylation at the N-Myc promoter and enhancer regions, which correlates with active transcription and is disrupted by inhibitors of acetyltransferases in cancer models. DNA methylation patterns at the promoter also influence accessibility, with hypomethylation facilitating expression during development and in aggressive tumors. N-Myc participates in feedback loops, including negative auto-regulation at high expression levels to maintain homeostasis in neuroblastoma cells. Furthermore, it responds to growth factors via BMP signaling, which upregulates N-Myc in cardiac and neural progenitors to coordinate proliferation.

Cellular Functions

Transcriptional Regulation

N-Myc functions as a transcription factor by forming obligate heterodimers with the partner protein Max through its basic helix-loop-helix leucine zipper (bHLH-LZ) domain, enabling the complex to bind specific DNA sequences known as E-box motifs, typically CANNTG, with a preference for CACGTG or CATGTG in promoter and enhancer regions. This dimerization is essential for DNA recognition, as N-Myc alone lacks stable binding capability. The N-Myc/Max complex exhibits cooperative binding when multiple E-box motifs are present in close proximity, enhancing overall affinity and stability at target sites, as observed in studies of Myc family proteins where adjacent E-boxes in genes like ornithine decarboxylase promote high-affinity interactions. For transcriptional activation, the N-Myc/Max heterodimer recruits coactivator complexes to modify and facilitate activity. Specifically, it interacts with the TIP60 complex, promoting and H4 to open structure at target promoters. Additionally, N-Myc engages the Mediator complex, which bridges the to the basal transcriptional machinery, thereby amplifying . These mechanisms drive the upregulation of genes involved in cellular processes such as and protein synthesis. In contrast, N-Myc can mediate transcriptional repression by associating with the zinc-finger protein Miz-1 at promoters lacking E-boxes, forming a complex that recruits deacetylases (HDACs), such as , to condense and inhibit transcription. This repression is evident at genes like TRKA and p75NTR in cells, where the SP1/Miz-1/N-Myc/ complex suppresses neuronal differentiation signals. Genome-wide followed by sequencing (ChIP-seq) studies in cell lines have identified thousands of N-Myc binding sites, with approximately 4,000 to 10,000 peaks depending on the model, many of which are enriched at genes regulating (e.g., glycolytic enzymes like and GAPDH) and (e.g., ribosomal proteins and nucleolin). These targets underscore N-Myc's role in amplifying biosynthetic pathways critical for rapidly proliferating cells.

Role in Proliferation and Differentiation

N-Myc plays a pivotal role in driving cell proliferation by facilitating the G1/S phase transition of the cell cycle. It achieves this by transcriptionally upregulating key cyclins, such as Cyclin D2, which forms complexes with cyclin-dependent kinases (CDKs) to phosphorylate the retinoblastoma protein (Rb), thereby releasing E2F transcription factors to promote S-phase entry. Concurrently, N-Myc represses the expression of the CDK inhibitor p21 (CDKN1A), which normally halts G1 progression by binding and inhibiting cyclin-CDK complexes; this downregulation allows unchecked advancement through the cell cycle checkpoint. These mechanisms collectively amplify proliferative signals in neural and other progenitor cells, ensuring rapid expansion during development. For instance, target genes like Cyclin D2 exemplify N-Myc's influence on cell cycle regulators, as detailed in broader transcriptional studies. In neural progenitors, N-Myc inhibits differentiation to maintain a stem-like, proliferative state. It represses pro-differentiation factors, thereby preventing premature exit from the progenitor pool and sustaining self-renewal. Simultaneously, N-Myc promotes the expression of stemness factors like LIN28B, which inhibits let-7 microRNAs to stabilize oncogenic transcripts and reinforce pluripotency networks, further blocking lineage commitment. This dual action—suppressing differentiation cues while enhancing maintenance—ensures balanced tissue growth during embryogenesis, with disruptions leading to impaired neural development. N-Myc induces metabolic reprogramming to support the bioenergetic demands of proliferating cells, particularly by enhancing and metabolism. It upregulates (LDHA), shifting pyruvate toward lactate production even in oxygen-rich conditions (aerobic glycolysis or Warburg effect), which generates ATP and biosynthetic intermediates for rapid division. Additionally, N-Myc drives uptake and utilization by activating glutaminase 2 (GLS2), converting to glutamate for tricarboxylic acid (TCA) cycle anaplerosis and synthesis, thereby fueling biomass production in high-demand states. These adaptations prioritize growth over , optimizing cellular fitness in proliferative contexts. Regarding , N-Myc exhibits context-dependent effects: it sensitizes cells to programmed death under genotoxic or nutrient stress by activating pro-apoptotic pathways, promoting elimination of damaged cells to prevent tumorigenesis. However, in proliferative or oncogenic settings, N-Myc is associated with increased expression of anti-apoptotic , which sequesters Bax/Bak to inhibit mitochondrial outer membrane permeabilization and activation, thus conferring resistance to stress-induced death. Experimental evidence from N-Myc knockout mice underscores its essential role in these processes, revealing embryonic lethality around E10.5-E11.5 with profound neural defects, including failure of closure, reduced proliferation, and impaired differentiation leading to and craniofacial abnormalities. Conditional s in neural tissues further confirm that N-Myc loss disrupts G1/S progression and metabolic shifts, resulting in depleted progenitor pools and halted .

Protein Interactions

Key Binding Partners

N-Myc forms an obligatory heterodimer with Max to enable DNA binding and transcriptional activity, as N-Myc lacks the capacity for homodimerization on its own. This interaction occurs through the basic helix-loop-helix leucine zipper (bHLH-LZ) domains of both proteins, with structural studies revealing that the N-Myc-Max heterodimer exhibits higher stability compared to Max homodimers due to enhanced hydrophobic interactions in the leucine zipper interface. Co-immunoprecipitation experiments have confirmed the direct binding affinity of N-Myc to Max, with dissociation constants in the nanomolar range observed in vitro for similar Myc-Max complexes. Aurora A kinase directly binds N-Myc and stabilizes it by preventing ubiquitination and proteasomal degradation, particularly by shielding it from the SCFFBXW7 E3 ligase complex after at Ser62 by CDK1 and Thr58 by GSK3β. This interaction is independent of Aurora A's catalytic activity in some contexts, relying instead on to shield N-Myc from the SCFFBXW7 E3 ligase complex, as demonstrated by co-immunoprecipitation assays showing robust association in cell lysates. The binding affinity is enhanced during , with Aurora A localizing to the nucleus to maintain elevated N-Myc levels. Members of the Rb family, such as , suppress N- transcriptional activation, potentially through indirect mechanisms or analogous to direct binding observed with c-. Co-immunoprecipitation studies have validated 's repressive role in control for the Myc family. In contrast, TRRAP serves as a scaffold in the activation complex, binding the N-Myc to recruit modules like SAGA and NuA4 for promoter and transcriptional enhancement. Endogenous co-immunoprecipitation in cancer cells confirms TRRAP's specific association with N-Myc-Max heterodimers at active promoters. Recent investigations as of 2025 have identified KLHL37 as a direct binder that enhances N-Myc stability by disrupting its interaction with the FBXW7 , thereby preventing degradation; co-immunoprecipitation assays in models demonstrate this binding occurs via the Kelch domain of KLHL37. Similarly, FAM13A interacts with N-Myc to modulate proliferation, where FAM13A knockdown reduces N-Myc protein levels and inhibits , as evidenced by co-immunoprecipitation showing direct complex formation in tumor cells.

Functional Interaction Networks

N-Myc integrates with the Wnt/β-catenin pathway by cooperating with β-catenin to drive target gene expression, thereby enhancing β-catenin transcriptional activity in contexts such as progenitor cell proliferation during . This interaction is particularly evident in neural and epithelial tissues, where N-Myc amplification in sustains Wnt signaling to promote tumor progression. N-Myc exhibits crosstalk with Notch signaling through regulation of the DLL3 ligand, forming an N-Myc-DLL3-Notch axis that controls maintenance and differentiation during development. In cancer, this crosstalk contributes to aggressive phenotypes in , where N-Myc amplification suppresses Notch-mediated differentiation to favor proliferation. Similarly, N-Myc interacts with the pathway, as Sonic signaling upregulates N-Myc expression in cerebellar granule neuron precursors, driving proliferation in neural development. In and , this reciprocal activation amplifies oncogenic growth, with N-Myc further modulating effectors like to sustain tumorigenesis. Beyond transcriptional roles, N-Myc functions as an , directly interacting with target mRNAs to influence their stability and , as revealed in integrative studies of the MYC family's RNA-binding . A 2025 analysis using enhanced crosslinking and sequencing (eCLIP-seq) across lines demonstrated that conserved motifs in the MYC basic region enable high-affinity binding to guanosine-rich RNA sequences, thereby modulating mRNA decay and translation efficiency to support oncogenic programs. This RNA-binding capability extends N-Myc's regulatory reach, stabilizing proliferation-associated transcripts in neural tumors. Network modeling using databases like and BioGRID positions N-Myc as a central hub in interconnected pathways, with high-confidence interactions linking it to over 200 partners enriched in and regulation. For instance, STRING analysis highlights N-Myc's coordination of ribosomal protein synthesis genes, such as those in the nucleolar complex, to drive biomass accumulation during rapid cell division. BioGRID further reveals dense connectivity to , including cyclins and CDKs, underscoring N-Myc's role in synchronizing G1/S progression with metabolic demands. N-Myc's functional networks exhibit dynamic, context-dependent rewiring between developmental and tumorigenic states, where it promotes controlled proliferation in embryonic neural tissues but drives uncontrolled growth upon amplification in cancer. In development, N-Myc integrates with transient signaling cues to balance differentiation, whereas in tumorigenesis, hyperactivation shifts networks toward sustained and evasion of brakes, as evidenced by differential target in models. This plasticity highlights N-Myc's adaptability, with pathway crosstalk amplifying oncogenic outputs in malignant contexts.

Pathological Roles

Involvement in Neuroblastoma

MYCN amplification occurs in approximately 20-25% of primary neuroblastoma tumors and is strongly associated with high-risk disease and poor prognosis. This genetic alteration, first identified in the early 1980s, serves as a key biomarker for aggressive tumor behavior, with amplified cases showing rapid progression, advanced staging at diagnosis, and reduced 5-year overall survival rates of around 50% compared to over 85% in non-amplified cases. Historically, the discovery of MYCN amplification in neuroblastoma cell lines by Schwab et al. in 1983 marked a pivotal advancement, leading to its rapid integration into clinical risk assessment by the mid-1980s. The primary mechanism underlying MYCN's oncogenic role involves gene dosage effects from amplification at chromosome 2p24, resulting in overexpression that drives uncontrolled , inhibits differentiation, and promotes metastatic spread. Overexpression enhances tumor aggressiveness by upregulating genes involved in progression (e.g., CDK4, ID2), (e.g., matrix metalloproteinases), and angiogenesis, while conferring resistance to apoptosis and metabolic adaptability. In this context, MYCN amplification acts as an early initiating event in neural crest-derived tumors, fostering the development of high-risk phenotypes. Detection of MYCN amplification is integral to clinical staging and risk stratification using systems like the International Neuroblastoma Staging System (INSS) and International Neuroblastoma Risk Group (INRG) classifications. on tumor tissue or serves as the gold standard, identifying amplification as a >4-fold increase in MYCN signals relative to reference probes, while quantitative PCR (qPCR) on plasma cell-free DNA offers a noninvasive alternative with high sensitivity (86.5%) and specificity (100%) via MYCN/NAGK ratios. These methods enable precise high-risk categorization, guiding intensified therapy for amplified cases. MYCN amplification contributes to intratumoral heterogeneity, particularly by enriching adrenergic cell states that support tumor-initiating potential and self-renewal. In relapsed neuroblastomas, persistent or evolving MYCN activity sustains aggressive subclones, often through enhancer hijacking or metabolic rewiring, leading to therapy resistance and poorer outcomes. Recent 2025 updates to the INRG system refine risk stratification by incorporating MYCN status alongside genomic and imaging data, improving prognostic accuracy for heterogeneous cases and informing trial eligibility.

Role in Other Cancers

N-Myc amplification and overexpression contribute to oncogenesis in several malignancies beyond neuroblastoma, including , , and small cell lung cancer (SCLC). In , MYCN amplification occurs in approximately 5-10% of cases, predominantly within the high-risk Group 3 subtype, where it drives aggressive tumor progression and is associated with metastatic dissemination. In , MYCN amplification is identified in 1-9% of tumors, often in RB1-proficient cases, promoting de-differentiation and early-onset disease with histological aggressiveness. Similarly, in SCLC, MYCN amplification is observed in about 20% of cases, frequently alongside RB1 and TP53 alterations, enhancing tumor initiation and variant subtype emergence. Within pediatric brain tumors, N-Myc plays a subtype-specific role in progression, particularly in Group 3 medulloblastoma, where it sustains embryonal features and poor outcomes through transcriptional dysregulation of proliferation pathways. Recent analyses highlight MYCN amplification in up to 15% of high-grade gliomas, correlating with epithelioid morphology and median overall survival of 91 months versus 112 months in non-amplified cases. In these tumors, MYCN frequently co-occurs with TP53 mutations, amplifying genomic instability and resistance to therapy. Mechanistically, N-Myc cooperates with ALK mutations in embryonal tumors resembling , where the ALK F1174L variant potentiates MYCN-driven oncogenesis by enhancing progression and , leading to synergistic tumor acceleration. Additionally, in solid tumors, MYCN induces metabolic reprogramming, including upregulated fatty acid uptake and synthesis, to support rapid proliferation and survival under nutrient stress. Prognostically, MYCN amplification correlates with inferior survival across these cancers; for instance, in , it is linked to less than 50% mean survival in fusion-positive subtypes, independent of other risk factors. Epidemiologically, MYCN amplification prevalence varies by tumor type—ranging from 14.7% in IDH-mutant gliomas to 5-10% in —and frequently co-occurs with TP53 mutations, exacerbating metastatic potential and therapeutic resistance.

Therapeutic Targeting

Inhibitor Development

Direct inhibitors of N-Myc aim to disrupt its transcriptional activity by targeting key structural domains or protein-protein interactions. A notable example is the N78, identified in a 2025 study as the first selective N-Myc inhibitor, which binds directly to N-Myc and promotes its proteasomal degradation without affecting other family members. N78 disrupts N-Myc/Max dimerization, suppresses expression of N-Myc target genes, and reduces cell viability in MYCN-amplified models. Additionally, like 10058-F4, originally developed for c-Myc, have been adapted to inhibit N-Myc/Max heterodimerization and DNA binding in neuroblastoma cells, demonstrating reduced proliferation in preclinical settings. Bromodomain and extra-terminal (, such as , indirectly target the N-Myc (TAD) by displacing from acetylated regions at the MYCN promoter and enhancer sites. This interference downregulates MYCN transcription and impairs N-Myc-driven gene expression in MYCN-amplified tumors. Indirect strategies exploit N-Myc's stabilizing interactions, such as with Aurora A , to promote its degradation. Aurora A inhibitors like alisertib (MLN8237) disrupt the Aurora A/N-Myc complex—where Aurora A binds the N-Myc TAD to prevent ubiquitination—leading to Fbxw7-mediated proteasomal degradation of N-Myc. Similarly, CDK inhibitors, including THZ1 targeting CDK7, block events that stabilize N-Myc and amplify its transcriptional output, resulting in downregulation of super-enhancer-linked oncogenic programs in MYCN-driven cancers. Antisense oligonucleotides () and proteolysis-targeting chimeras (PROTACs) offer nucleic acid- and degradation-based approaches for MYCN knockdown. , such as those targeting MYCN mRNA, achieve efficient knockdown in cells, inducing differentiation and while reducing tumor growth in xenograft models. PROTACs, including dual Aurora A/B degraders like dAurAB5, recruit ligases to ubiquitinate and degrade Aurora A, thereby destabilizing N-Myc and suppressing its activity in MYCN-amplified cell lines. In preclinical models, these inhibitors demonstrate efficacy by inducing tumor regression through reduced proliferation and increased in MYCN-amplified . For instance, N78 treatment led to significant tumor shrinkage with enhanced potency over non-selective analogs, while alisertib promoted N-Myc degradation and halted growth in patient-derived xenografts. like similarly caused rapid downregulation of MYCN expression and tumor stasis in orthotopic models. Development of N-Myc inhibitors faces challenges, including achieving selectivity over c-Myc to minimize off-target effects in normal tissues, as many early compounds like MYCi975 exhibit cross-reactivity across MYC family proteins. Toxicity profiles remain a concern, with some agents causing reversible side effects like gastrointestinal issues, though selective inhibitors like N78 show improved tolerability in preclinical dosing.

Clinical and Research Advances

Recent clinical trials have advanced N-Myc targeting in , with phase II studies evaluating chimeric antigen receptor () T-cell therapies directed against antigens influenced by MYCN amplification, such as L1CAM, to improve responses in high-risk patients. These approaches address limitations like T-cell exhaustion observed in GD2-targeted CAR-T trials, prioritizing MYCN-driven subtypes for better tumor infiltration and persistence. Additionally, combination therapies integrating immunotherapy agents like the anti-GD2 antibody or 14G2a with Aurora kinase inhibitors are under investigation, showing synergistic effects in preclinical models of MYCN-amplified and progressing toward clinical evaluation to enhance overall survival. In 2025, key research breakthroughs elucidated the role of Neurog2 in MYCN-driven neuroendocrine plasticity, particularly in models where Neurog2 depletion selectively suppressed growth of MYCN-overexpressing cells without affecting non-malignant ones, suggesting its potential as a therapeutic target in N-Myc-associated neuroendocrine tumors. Concurrently, disruption of the KLHL37-N-Myc complex was shown to restore N-Myc degradation via enhanced ubiquitination, arresting tumor growth in MYCN-amplified mouse models and highlighting KLHL37 as a vulnerability for stability modulation. Biomarker developments have focused on liquid biopsies using droplet digital PCR to detect MYCN copy number variations in , enabling non-invasive monitoring of relapse in patients and correlating plasma levels with surgical outcomes and disease progression. This approach facilitates real-time assessment of MYCN amplification status, improving risk stratification and early intervention for high-risk subsets. Future directions include CRISPR-based editing in models, where nickase systems selectively target MYCN-amplified regions to induce cancer cell death while sparing normal cells, as demonstrated in proof-of-concept studies. AI-driven target prediction is also emerging, with models analyzing and genomic data to forecast MYCN amplification and identify novel interaction partners like FAM13A for therapeutic intervention. These tools promise personalized strategies in preclinical and clinical settings. Targeted regimens have yielded improved survival rates in subsets with low MYCN amplification, where 5-year overall survival exceeds 90% compared to 50% in amplified cases, underscoring the impact of precision therapies on intermediate-risk groups.

References

  1. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/n-myc
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3869278/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC367228/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9920120/
  5. https://www.ncbi.nlm.nih.gov/gene/4613
  6. https://omim.org/entry/164840
  7. https://www.ensembl.org/id/ENST00000281043
  8. https://www.uniprot.org/uniprotkb/P04198/entry
  9. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYCN
  10. https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-9-445
  11. https://pubmed.ncbi.nlm.nih.gov/2869488/
  12. https://www.informatics.jax.org/marker/MGI:97357
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC7886978/
  14. https://aacrjournals.org/cancerdiscovery/article/8/2/150/6266/The-Expanding-World-of-N-MYC-Driven-TumorsThe
  15. https://portlandpress.com/biochemj/article/481/21/1535/235051/Exploring-the-dynamics-and-interactions-of-the-N
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC7226237/
  17. https://aacrjournals.org/mcr/article/12/6/815/89466/The-N-myc-Oncogene-Maximizing-its-Targets
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC9984901/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC187459/
  20. https://pubmed.ncbi.nlm.nih.gov/1986001/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4349441/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC6310397/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4067544/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC3760152/
  25. https://www.nature.com/articles/s41416-022-01988-z
  26. https://pubmed.ncbi.nlm.nih.gov/15382088/
  27. https://pubmed.ncbi.nlm.nih.gov/23063798/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3904094/
  29. https://academic.oup.com/nar/article/25/8/1493/1093529
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC1319201/
  31. https://pubmed.ncbi.nlm.nih.gov/21123453/
  32. https://aacrjournals.org/cancerres/article/71/2/404/568270/A-SP1-MIZ1-MYCN-Repression-Complex-Recruits-HDAC1
  33. https://www.nature.com/articles/s41389-023-00477-z
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC145518/
  35. https://genesdev.cshlp.org/content/16/20/2699.long
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4747359/
  37. https://pubmed.ncbi.nlm.nih.gov/9751117/
  38. https://pubmed.ncbi.nlm.nih.gov/8256847/
  39. https://www.nature.com/articles/cddis201442
  40. https://www.cell.com/cell/pdf/S0092-8674(02)01284-9.pdf
  41. https://www.nature.com/articles/s41598-018-28107-4
  42. https://www.sciencedirect.com/science/article/pii/S153561080800408X
  43. https://www.cell.com/cancer-cell/fulltext/S1535-6108(13)00232-8
  44. https://www.nature.com/articles/s41388-021-01766-w
  45. https://www.embopress.org/doi/full/10.1002/j.1460-2075.1994.tb06725.x
  46. https://www.cell.com/current-biology/pdf/S0960-9822(95)00173-4.pdf
  47. https://www.nature.com/articles/ncomms81479
  48. https://www.jci.org/articles/view/176655
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC11907995/
  50. https://journals.biologists.com/dev/article/144/22/4173/48228/Myc-cooperates-with-catenin-to-drive-gene
  51. https://aacrjournals.org/cancerres/article/81/8/2157/670575/Activated-ALK-Cooperates-with-N-Myc-via-Wnt
  52. https://www.sciencedirect.com/science/article/pii/S1534580709002937
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC10179553/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4302450/
  55. https://aacrjournals.org/cancerres/article/71/15/5336/568054/Sequential-Activation-of-Snail1-and-N-Myc
  56. https://pubmed.ncbi.nlm.nih.gov/40378850/
  57. https://doi.org/10.1016/j.xgen.2025.100878
  58. https://string-db.org/network/9606.ENSP00000347997
  59. https://www.embopress.org/doi/10.1093/emboj/20.6.1383
  60. https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.0020332
  61. https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-024-10282-6
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC9496712/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC3784814/
  64. https://pubmed.ncbi.nlm.nih.gov/6719137/
  65. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.624079/full
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC7873735/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7607162/
  68. https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf242/8240848
  69. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.623679/full
  70. https://www.sciencedirect.com/science/article/pii/S0039625724000559
  71. https://www.sciencedirect.com/science/article/pii/S1535610816306006
  72. https://thepathologist.com/issues/2025/articles/september/mycn-amplification-predicts-poor-outcomes-in-gliomas/
  73. https://www.nature.com/articles/s41467-023-43564-w
  74. https://www.embopress.org/doi/10.15252/embj.2020105784
  75. https://www.nature.com/articles/s41467-022-31331-2
  76. https://www.medrxiv.org/content/10.1101/2024.09.04.24313032v1.full-text
  77. https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/2056-4538.70045
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC12374823/
  79. https://pubmed.ncbi.nlm.nih.gov/40860201/
  80. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0097285
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC3672953/
  82. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1683331/full
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC4298657/
  84. https://www.cell.com/cell/fulltext/S0092-8674%2814%2901312-9
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC2708968/
  86. https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202400703
  87. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1601975/full
  88. https://www.sciencedirect.com/science/article/pii/S1043661825000337
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC11913827/
  90. https://link.springer.com/article/10.1007/s10495-018-1472-9
  91. https://www.nature.com/articles/s41388-025-03413-0
  92. https://www.oncotarget.com/article/19076/text/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC11197818/
  94. https://www.nature.com/articles/s41467-025-60160-2
  95. https://ar.iiarjournals.org/content/43/9/3829
Add your contribution
Related Hubs
User Avatar
No comments yet.